Team

Arix Bioscience has been formed by leading figures in the international healthcare and life science sectors. Dr Joe Anderson, Chief Executive Officer, is a former partner with Abingworth LLP and has 25 years’ experience of identifying and building successful businesses. Jonathan Peacock, Chairman, is the former Chief Financial Officer of Amgen and Novartis Pharma and has deep M&A, strategic and operational expertise. Professor Sir Christopher Evans, OBE, Deputy Chairman, is one of Europe’s most successful entrepreneurs in the life science sector with a track record of success spanning 30 years. The founders’ significant complementary expertise in generating value covers a wide range of healthcare and life science disciplines, from academia science, through clinical and commercial strategy, company operations, venture capital, M&A and also corporate finance. Collectively, the senior team has founded, developed and operated multiple life science companies, both large and small, and has contributed significantly to the creation of substantial value for shareholders. The founders lead a team with a unique combination of entrepreneurial, investing and operating skills which is supported by a highly experienced board of directors.

Corporate Strategy

Arix Bioscience’s business strategy is to source, finance and develop both start-up and later-stage companies in the healthcare and life science sectors globally.

Through our access to innovative science, extensive management experience and the patient deployment of capital, we are committed to helping such companies progress their businesses and maximise value for investors.

We aim to utilise our expertise and experience to build an international group of healthcare and life science businesses.

The entrepreneurial sourcing and operational experience of Arix Bioscience and the diverse range of life science opportunities under consideration have proved attractive to investors.

Arix Bioscience raised substantial, initial operational and investment capital from a range of investors, led by Woodford Investment Management LLP. This capital enabled us to create a truly flexible business platform.

Our evergreen structure permits further capital raising, which will continue as our business develops. The company has access to an extensive pipeline of deals and current market conditions are creating further opportunities.